-+ 0.00%
-+ 0.00%
-+ 0.00%

MetaVia reports preclinical data showing obesity drug DA-1726 concentrates in adipose tissue

PUBT·09/09/2026 12:02:33
Listen to the news
MetaVia reports preclinical data showing obesity drug DA-1726 concentrates in adipose tissue
  • MetaVia disclosed preclinical tissue-distribution results supporting its obesity drug candidate DA-1726, reinforcing its rationale for reducing waist size.
  • Findings point to preferential exposure in fat tissue with prolonged retention, consistent with the program’s once-weekly dosing profile.
  • Management tied the data to previously presented Phase 1 results showing meaningful waistline reductions, citing tolerability consistent with limited brain exposure.
  • Topline results from an ongoing 24-week dose-titration study are scheduled for release at 16 weeks in Q4 2026.
  • Topline results from the full 24-week readout are expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609090800PR_NEWS_USPR_____NY42836) on September 09, 2026, and is solely responsible for the information contained therein.